RESUMEN
Starting from the tetrahydroisoquinoline SB-277011 1, a novel series of 5-substituted-2,3-dihydro-1H-isoindoles has been designed. Subsequent optimisation resulted in identification of 19, which has high affinity for the dopamine D3 receptor (pKi 8.3) and > or = 100-fold selectivity over other aminergic receptors. In rat studies 19 was brain penetrant with an excellent pharmacokinetic profile (oral bioavailability 77%, t1/2 5.2h).
Asunto(s)
Antagonistas de Dopamina/química , Antagonistas de Dopamina/farmacología , Indoles/química , Indoles/farmacología , Receptores de Dopamina D2/metabolismo , Animales , Encéfalo/metabolismo , Células CHO , Cricetinae , Antagonistas de Dopamina/síntesis química , Antagonistas de Dopamina/metabolismo , Diseño de Fármacos , Humanos , Indoles/síntesis química , Indoles/metabolismo , Modelos Moleculares , Estructura Molecular , Ensayo de Unión Radioligante , Ratas , Receptores de Dopamina D3RESUMEN
This study utilizes the GM/KM immunoglobulin allotype system to elucidate the phylogenetic relationships of sub-Saharan Africans. The importance of understanding the relatedness of these peoples stems from the sub-Saharan region being the possible birthplace of humans. Haplotype distributions were determined for 19 populations and compared using chi-square analysis. Published data of other sub-Saharan Africans and representative populations worldwide were also added for comparison. Genetic distances between populations were calculated based on haplotype frequencies, and genetic relationships were observed through principal components analysis. Data from the GM/KM system showed a genetic homogeneity of the Bantu populations, with some exceptions, supporting the possibility of a common origin of these peoples. The Malagasy appeared as a divergent population, most likely due to Southeast Asian/Austronesian admixture, as indicated by the presence of the GM*AF B haplotype. The Cape Coloured also showed a divergence, with their genetic structures containing Caucasoid and Khoisan contributions. Finally, the Mbuti Pygmies appeared genetically isolated and had the highest frequency of the GM*A B haplotype out of all studied populations.
Asunto(s)
Población Negra/genética , Frecuencia de los Genes/genética , Variación Genética/genética , Haplotipos/genética , Alotipos de Inmunoglobulina Gm/genética , Alotipos Km de Inmunoglobulina/genética , Filogenia , África del Sur del Sahara , Distribución de Chi-Cuadrado , Etnicidad/genética , Análisis Factorial , Pool de Genes , Humanos , Lingüística , FenotipoRESUMEN
Starting from the dopamine D3 receptor antagonist SB-277011 1, a series of 2,3,4,5-tetrahydro-1H-3-benzazepines has been identified with high affinity for the dopamine D3 receptor and selectivity over the D2 receptor. The 3-acetamido-2-fluorocinnamide derivative 20 gave high D3 receptor affinity (pKi 8.4) with 130-fold selectivity over the 2, receptor.
Asunto(s)
Nitrilos/farmacología , Quinolinas/farmacología , Receptores de Dopamina D2/efectos de los fármacos , Tetrahidroisoquinolinas , Animales , Nitrilos/química , Quinolinas/química , Ratas , Receptores de Dopamina D3RESUMEN
The dopaminergic system has long been implicated in the mechanisms of reward and addiction. 1-(4-(2-Naphthoylamino)butyl)-4-(2-methoxyphenyl)-1A-piperazine HCl (BP 897) has been claimed to be a selective dopamine D3 receptor partial agonist and has recently been shown to inhibit cocaine-seeking behaviour, suggesting a role for dopamine D3 receptor agonists in the treatment of addiction. We have previously characterised the pharmacological profile of the human dopamine D3 and D2(long) receptors using microphysiometry and radioligand binding and we have now studied the interaction of BP 897 with the dopamine D2 and D3 receptors using these methods. At both human dopamine D3 and D2 receptors, BP 897 lacked agonist activity but was a potent and selective antagonist with pK(b) values of 8.05+/-0.16 (4) and 9.43+/-0.22 (4) at human dopamine D2 and D3 receptors, respectively. These results, therefore, suggest that it may be the dopamine D3 receptor antagonist properties of BP 897 which have potential in the treatment of addiction and withdrawal.
Asunto(s)
Agonistas de Dopamina/farmacología , Piperazinas/farmacología , Receptores de Dopamina D2/efectos de los fármacos , Animales , Azepinas/farmacología , Células CHO , Cricetinae , Humanos , Quinpirol/farmacología , Receptores de Dopamina D2/fisiología , Receptores de Dopamina D3RESUMEN
SB-277011-A (trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolininecarboxamide), is a brain-penetrant, high-affinity, and selective dopamine D(3) receptor antagonist. Radioligand-binding experiments in Chinese hamster ovary (CHO) cells transfected with human dopamine D(3) or D(2 long) (hD(3), hD(2)) receptors showed SB-277011-A to have high affinity for the hD(3) receptor (pK(i) = 7.95) with 100-fold selectivity over the hD(2) receptor and over 66 other receptors, enzymes, and ion channels. Similar radioligand-binding data for SB-277011-A were obtained from CHO cells transfected with rat dopamine D(3) or D(2). In the microphysiometer functional assay, SB-277011-A antagonized quinpirole-induced increases in acidification in CHO cells overexpressing the hD(3) receptor (pK(b) = 8.3) and was 80-fold selective over hD(2) receptors. Central nervous system penetration studies showed that SB-277011-A readily entered the brain. In in vivo microdialysis studies, SB-277011-A (2. 8 mg/kg p.o.) reversed the quinelorane-induced reduction of dopamine efflux in the nucleus accumbens but not striatum, a regional selectivity consistent with the distribution of the dopamine D(3) receptor in rat brain. SB-277011-A (2-42.3 mg/kg p.o.) did not affect spontaneous locomotion, or stimulant-induced hyperlocomotion. SB-277011-A (4.1-42.2 mg/kg p.o.) did not reverse prepulse inhibition deficits in apomorphine- or quinpirole-treated rats, but did significantly reverse the prepulse inhibition deficit in isolation-reared rats at a dose of 3 mg/kg p.o. SB-277011-A (2.5-78. 8 mg/kg p.o.) was noncataleptogenic and did not raise plasma prolactin levels. Thus, dopamine D(3) receptor blockade produces few of the behavioral effects characteristic of nonselective dopamine receptor antagonists. The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D(3) receptors may benefit the treatment of schizophrenia.
Asunto(s)
Antagonistas de Dopamina/farmacología , Nitrilos/farmacología , Quinolinas/farmacología , Receptores de Dopamina D2/efectos de los fármacos , Tetrahidroisoquinolinas , Animales , Encéfalo/metabolismo , Células CHO , Catalepsia/inducido químicamente , Cricetinae , Antagonistas de Dopamina/metabolismo , Antagonistas de Dopamina/toxicidad , Humanos , Masculino , Microdiálisis , Actividad Motora/efectos de los fármacos , Nitrilos/metabolismo , Nitrilos/toxicidad , Prolactina/sangre , Quinolinas/metabolismo , Quinolinas/toxicidad , Ensayo de Unión Radioligante , Ratas , Ratas Endogámicas , Ratas Sprague-Dawley , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3 , Reflejo de Sobresalto/efectos de los fármacos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , TransfecciónRESUMEN
A selective dopamine D(3) receptor antagonist offers the potential for an effective antipsychotic therapy, free of the serious side effects of currently available drugs. Using clearance and brain penetration studies as a screen, a series of 1,2,3, 4-tetrahydroisoquinolines, exemplified by 13, was identified with high D(3) affinity and selectivity against the D(2) receptor. Following examination of molecular models, the flexible butyl linker present in 13 was replaced by a more conformationally constrained cyclohexylethyl linker, leading to compounds with improved oral bioavailability and selectivity over other receptors. Subsequent optimization of this new series to improve the cytochrome P450 inhibitory profile and CNS penetration gave trans-N-[4-[2-(6-cyano-1, 2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarbo xamide (24, SB-277011). This compound is a potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and brain penetration in the rat and represents an excellent new chemical tool for the investigation of the role of the dopamine D(3) receptor in the CNS.
Asunto(s)
Sistema Nervioso Central/metabolismo , Antagonistas de Dopamina/síntesis química , Nitrilos/síntesis química , Quinolinas/síntesis química , Receptores de Dopamina D2/efectos de los fármacos , Tetrahidroisoquinolinas , Animales , Disponibilidad Biológica , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Células CHO , Catalepsia/inducido químicamente , Catalepsia/psicología , Sistema Nervioso Central/efectos de los fármacos , Cricetinae , Antagonistas de Dopamina/farmacocinética , Antagonistas de Dopamina/farmacología , Semivida , Humanos , Masculino , Microdiálisis , Nitrilos/farmacocinética , Nitrilos/farmacología , Prolactina/sangre , Quinolinas/farmacocinética , Quinolinas/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D3RESUMEN
A novel series of 5,6,7,8-tetrahydroquinazolines, 4,5,6,7-tetrahydroindazoles and 4,5,6,7-tetrahydrobenzothiazoles has been prepared, having high affinity and selectivity for the dopamine D3 receptor. The 4-methoxy-5,6,7,8-tetrahydroquinazoline 6i and 2-amino-4,5,6,7-tetrahydrobenzothiazole 8 proved to be agonists with among the highest D3 receptor affinities and selectivities reported to date.
Asunto(s)
Compuestos Heterocíclicos/química , Receptores de Dopamina D2/metabolismo , Tetrahidronaftalenos/química , Compuestos Heterocíclicos/metabolismo , Unión Proteica , Receptores de Dopamina D3 , Tetrahidronaftalenos/metabolismoRESUMEN
Using clearance and brain penetration studies as a screen, tetrahydroisoquinoline 3 was identified as a lead having low clearance in rats (CLb 20 ml/min/kg). Introduction of a 7-CF3SO2O- substituent into the tetrahydroisoquinoline, followed by replacement of the biphenylamido group of 3 by a 3-indolylpropenamido group gave 31, having high D3 receptor affinity (pKi 8.4) and 150 fold selectivity over the D2 receptor.
Asunto(s)
Isoquinolinas/síntesis química , Isoquinolinas/farmacología , Receptores de Dopamina D2/química , Animales , Encéfalo/efectos de los fármacos , Isoquinolinas/administración & dosificación , Isoquinolinas/sangre , Modelos Moleculares , Ratas , Receptores de Dopamina D3RESUMEN
Starting from a series of 2-aminotetralins 1, a novel series of N-[4-(4-phenylbenzoylamino)butyl]-octahydrobenzoquinolines and hexahydrobenzoindoles with high potency and selectivity for the dopamine D3 receptor has been designed. The effect of ligand chirality on binding affinity has been established. Selected derivatives (e.g. 2o, 2p) show high functional selectivity and enhanced in vivo properties compared to 1.
Asunto(s)
Antagonistas de los Receptores de Dopamina D2 , Tetrahidronaftalenos/química , Animales , Tasa de Depuración Metabólica , Ratas , Receptores de Dopamina D3 , Tetrahidronaftalenos/farmacocinética , Tetrahidronaftalenos/farmacologíaRESUMEN
Significant hearing loss and external pinna malformations are two of the most common defects evident in Down's syndrome. The external and middle ears are linked embryologically, both arising from the first and second branchial arches. Evidence indicates that the majority of hearing loss in Down's syndrome is conductive in nature, originating from malformations of the middle ear ossicles and/or the eustachian tube. Recent studies also have indicated that hearing loss is a contributing factor to the IQ and learning deficits that afflict most individuals with Down's syndrome. Therefore, an early, external diagnostic feature for predicting conductive hearing loss would be desirable. In the current study, people with Down's syndrome, people with non-Down's mental retardation and control subjects were examined in a clinical environment for the presence of hearing loss and pinna defects. It was found that 90% of the Down's syndrome population had significant hearing loss, compared to slightly more than 50% in the non-Down's group and no hearing loss in the controls. Also, the majority of hearing loss among individuals with Down's syndrome was conductive, while all hearing loss in the non-Down's group was sensorineural. The Down's syndrome population exhibited nearly 3.5 pinna defects per ear, with malformations of the helix being very evident. The non-Down's population exhibited 2.5 pinna defects per ear, with concha defects being the most common.
Asunto(s)
Síndrome de Down/genética , Pérdida Auditiva Conductiva/genética , Adolescente , Adulto , Niño , Preescolar , Síndrome de Down/diagnóstico , Oído Medio/anomalías , Femenino , Pérdida Auditiva Conductiva/diagnóstico , Pérdida Auditiva Sensorineural/diagnóstico , Pérdida Auditiva Sensorineural/genética , Pruebas Auditivas , Humanos , Lactante , Masculino , Persona de Mediana EdadRESUMEN
Mice that were homozygous recessive for the single-gene mutation, hotfoot, showed profound and progressive motor disturbances in an open field after approximately the 4th postnatal week. Studies were undertaken to examine the role of the monoaminergic system in the behavioral and developmental expression of this neurological mutation. Relative to controls, 10-and 30-day-old hotfoot mice demonstrated a significantly attenuated response to the stimulating locomotor effects of amphetamine while adult hotfoot mice were motorically unaffected by amphetamine administration. 30-day-old and adult hotfoot mice also were hypothermic relative to phenotypically normal mice after amphetamine administration. Examination of monoamine levels and turnover revealed that hotfoot mice had significantly greater concentrations of norepinephrine associated with lower turnover in cerebellum and greater levels of serotonin in cerebellum and striatum, relative to phenotypic controls. In addition, mice born and raised by hotfoot dams demonstrated neurochemical alterations regardless of genotype. Both the neurochemical data and the developmental response to the general catecholamine agonist, amphetamine, suggest that the monaminergic neurotransmitter system may be altered as a consequence of the hotfoot mutation.
Asunto(s)
Ataxia/genética , Ataxia/metabolismo , Monoaminas Biogénicas/metabolismo , Sistema Nervioso Central/metabolismo , Actividad Motora/fisiología , Mutación , Envejecimiento/fisiología , Anfetamina/farmacología , Animales , Temperatura Corporal , Peso Corporal , Cerebelo/metabolismo , Cuerpo Estriado/metabolismo , Genotipo , Ratones , Ratones Mutantes Neurológicos/genética , Actividad Motora/efectos de los fármacos , Neurotransmisores/metabolismoRESUMEN
We analyzed prospective data from 19,889 elderly residents of 51 nursing homes from 1984 to 1985 to determine the prevalence, incidence, and natural history of pressure ulcers. Among all residents admitted to nursing homes, 11.3% possessed a stage II through stage IV pressure ulcer. For those residents admitted to the nursing home without pressure ulcers during the study period, the 1-year incidence was 13.2%. This increased to 21.6% by 2 years of nursing home stay. People already residing in a nursing home at the start of the study had a 1-year incidence of 9.5%, which increased to 20.4% by 2 years. Pressure ulcers were associated with an increased rate of mortality, but not hospitalization. Longitudinal follow-up of residents with pressure ulcers demonstrated that a majority of their lesions were healed by 1 year. Most of the improvement occurred early in a person's nursing home stay. Although nursing home residents with pressure ulcers have a higher mortality, with good medical care pressure ulcers can be expected to heal.
Asunto(s)
Casas de Salud , Úlcera por Presión/epidemiología , Anciano , Anciano de 80 o más Años , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Úlcera por Presión/fisiopatología , Úlcera por Presión/terapia , Prevalencia , Análisis de Supervivencia , Estados Unidos/epidemiologíaRESUMEN
Audiogenic seizure susceptibility was studied in mice segregating for the microphthalmic white gene (Miwh). Previous work by Deol had indicated that mice with either one or two Miwh alleles had severe inner ear defects. A congenic inbred strain provided mice that were identical in genetic background except for single-gene substitutions at the microphthalmia locus. The three genotypes tested were Miwh/Miwh, Miwh/+, and +/+. Mice were exposed to the sound stimulus once for a 1-min period between the ages of 17 and 30 days. Heterozygous Miwh/+ mice had more seizures and were more reactant than either type of homozygote at all ages tested. Responses were low at 17 days of age, peaked sharply by 23 days, and declined markedly by 30 days.
Asunto(s)
Ratones Mutantes Neurológicos/genética , Microftalmía/genética , Convulsiones/genética , Estimulación Acústica , Animales , Color del Cabello/genética , Heterocigoto , Homocigoto , Ratones , FenotipoAsunto(s)
Acampada , Bachillerato en Enfermería , Distrofias Musculares/enfermería , Neoplasias/enfermería , California , Niño , Humanos , MasculinoRESUMEN
The synthesis and antihypertensive activity of a series of novel 4-(cyclic amido)-2H-1-benzopyran-3-ols, administered orally to conscious spontaneously hypertensive rats, are described. The effects of lactam ring size, the presence of heteroatoms in the lactam ring, substitution at C(2) and C(3), relative stereochemistry at C(3) and C(4), and aromatic substitution pattern on the blood pressure lowering activity of this series have been determined. The key compound 2 from this work [BRL 34915; (+/-)-6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxopyrrolidin-1- yl)-2H-1-benzopyran-3-ol] has been resolved, and antihypertensive activity was found to reside primarily in the (-) enantiomer. The key step in the preparation of this class of compounds is the action of a cyclo amidic anion on an appropriate epoxide. Another approach, involving a cyclization step to the lactam was found to be more convenient in certain cases, particularly in forming the cis analogue of compound 2. Compound 2 has been shown to possess a novel mechanism of action, and it has been selected for progression to the clinic.
Asunto(s)
Antihipertensivos/síntesis química , Benzopiranos/síntesis química , Animales , Antihipertensivos/farmacología , Benzopiranos/farmacología , Ratas , Ratas Endogámicas SHR , Relación Estructura-ActividadRESUMEN
Effects of abnormal neural tube development were studied in immature and adult mice. The behavior of affected adult mice was found to resemble that of mice that exhibit the "waltzer syndrome." Behavioral ontogenetic studies indicate that effected mice are deficient in labyrinthine responses as shown by the late development or lack of negative geotaxic behaviors and the delayed loss of pivoting behavior. Retarded maturation of neural responses was indicated by a delay in the appearance of the startle response. Evidence that circling behavior in adult mice of the "waltzer syndrome" may be a result of central nervous system disorders alone, or in concert with abnormalities of the inner ear, was provided by the fact that open field activity was increased in affected mice that exhibit circling behavior as adults.